FRESENIUS SE, Divestment of the loss-making Biotech division and completion of Fenwal acquisition

News published on December Friday 14, 2012
Share on
As expected, Fresenius SE has decided to focus on its 4 key franchises: Kabi, Medical Care, Helios and Vamed. Therefore the company will shut its Biotech division which was making losses despite having two products on the market (9M 2012: EUR26m of sales, +15%). In FY 2012, operational losses will reach around EUR25m and have a negative impact on group EBIT margin of 20 bps.

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities